Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Gynecologic 2Breast 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Breast Neoplasms 75Neoplasm Metastasis 12Neoplasms 8Ovarian Neoplasms 6Endometrial Neoplasms 6Pancreatic Neoplasms 5Carcinoma, Renal Cell 5Sarcoma 4Neoplasms by Site 4Lymphoma, Non-Hodgkin 4Breast Diseases 4Squamous Cell Carcinoma of Head and Neck 3Multiple Myeloma 3Lymphoma 3Lung Neoplasms 3Liposarcoma 3Kidney Neoplasms 3Head and Neck Neoplasms 3Glioma 3Wilms Tumor 2Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Recurrence 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2

Interventions

pembrolizumab 34Cisplatin 29Paclitaxel 15Brachytherapy 15Radiotherapy 14Carboplatin 14Bevacizumab 14Blood Specimen Collection 13Specimen Handling 12Magnetic Resonance Spectroscopy 11Colposcopy 11Nivolumab 10Drug Therapy 10atezolizumab 8Human Papillomavirus DNA Tests 8Gemcitabine 8lenvatinib 7Radiation 6Platinum 6Biopsy 6toripalimab 5cemiplimab 5Surveys and Questionnaires 5Standard of Care 5Radiotherapy, Intensity-Modulated 5Practice Guidelines as Topic 5Patient Navigation 5Fulvestrant 5Fluorodeoxyglucose F18 5zimberelimab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × palbociclib × 1 year × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡